Alpharine 10 mg (90 Tablets) – Ostarine (MK-2866) | Omega Lab
Product Overview
Alpharine 10 mg is an oral tablet product marketed under the Omega Lab name. According to the supplied Roidsdeal and Finest Gears descriptions, each tablet contains 10 mg of ostarine (MK-2866), and each package contains 90 tablets.
Ostarine, also known as enobosarm, is an investigational selective androgen receptor modulator (SARM). It has been studied for its potential effects on lean body mass, muscle function, and conditions involving muscle loss.
Unlike approved prescription medications, ostarine has not received FDA approval for human use in the United States.
The supplied descriptions associate Alpharine with muscle definition, strength, and lean mass preservation. However, these marketing claims do not establish proven clinical benefits or safety for this particular product.
The manufacturing standards, independent laboratory testing, and regulatory authorization of Omega Lab Alpharine 10 have not been verified.
What Is Alpharine 10?
Alpharine 10 is described as a tablet formulation containing ostarine, also identified as MK-2866.
Ostarine is a nonsteroidal selective androgen receptor modulator developed for research into androgen-related biological pathways.
SARMs are designed to interact with androgen receptors while potentially producing different tissue responses compared with traditional anabolic-androgenic steroids.
Although ostarine is not structurally classified as an anabolic steroid, it influences androgen receptor signaling and may produce systemic hormonal effects.
The term “selective” refers to its intended pharmacological activity and does not mean that the compound affects only skeletal muscle or is free from adverse reactions.
Ostarine remains an investigational substance rather than an approved general-purpose muscle-building or weight-management medication.
How Does Ostarine Work?
Ostarine interacts with androgen receptors, which are intracellular proteins involved in regulating cellular responses to androgenic compounds.
Androgen receptors are found in several tissues, including skeletal muscle, bone, and reproductive structures.
When activated, these receptors can influence gene transcription and biological pathways related to protein metabolism, tissue maintenance, and other physiological processes.
Ostarine was developed to investigate whether selective androgen receptor activity could produce useful effects in muscle and bone while limiting certain unwanted effects associated with conventional androgenic compounds.
However, tissue selectivity is relative rather than absolute.
Ostarine can influence endocrine feedback mechanisms, and hormonal suppression has been reported in connection with SARM exposure.
Its effects on muscle tissue do not establish that it safely improves athletic performance or produces predictable body-composition changes.
Clinical outcomes depend on the population studied, the research setting, and the endpoints being evaluated.
Medical Uses & Clinical Information
Ostarine has been investigated in clinical research involving muscle loss, lean body mass, and certain conditions associated with physical decline.
Research programs have explored selective androgen receptor modulation in populations experiencing muscle-related complications.
Some clinical studies have reported changes in lean body mass. However, changes in body composition are not equivalent to demonstrated improvements in long-term health, functional performance, or clinical outcomes.
Ostarine has not received FDA approval for treating muscle wasting, osteoporosis, obesity, or any other medical condition in the United States.
It is also not approved for bodybuilding, athletic performance enhancement, or cosmetic body recomposition.
The supplied Roidsdeal description claims that Alpharine improves strength, reduces body fat without hormonal side effects, and supports cutting cycles.
These claims are not established approved therapeutic benefits.
Ostarine and other SARMs are prohibited in competitive sports under World Anti-Doping Agency regulations.
Product Specifications & Packaging
| Specification | Details |
|---|---|
| Product Name | Alpharine 10 |
| Manufacturer | Omega Lab |
| Active Ingredient | Ostarine |
| Alternative Names | MK-2866 / Enobosarm |
| Labeled Strength | 10 mg per Tablet |
| Product Form | Oral Tablet |
| Package Size | 90 Tablets |
| Administration Route | Oral |
| Pharmacological Classification | Selective Androgen Receptor Modulator |
| US Regulatory Status | Not FDA-Approved for Human Use |
| Product-Specific Clinical Approval | Not Established |
Both supplied sources agree on the manufacturer, active ingredient, tablet strength, and package quantity.
However, the exact inactive ingredients, manufacturing standards, batch-testing results, and authenticity of the finished product remain unverified.
Administration & Medical Supervision
Alpharine 10 is described as an oral tablet product.
The stated strength of 10 mg per tablet identifies the reported quantity of ostarine but does not establish an appropriate or safe human dose.
Because ostarine is an investigational compound without FDA approval, there are no FDA-approved human dosing instructions for this product.
Medical evaluation of suspected SARM-related adverse effects may involve assessment of liver function, cardiovascular risk factors, cholesterol concentrations, and reproductive hormone levels.
The tablet-splitting quantities included in the competitor description should not be interpreted as recommended doses.
Similarly, bodybuilding cycles, cutting protocols, and combinations with other performance-enhancing substances are not established medical treatment regimens.
Professional supervision does not independently establish the safety of an unapproved investigational product.
Possible Side Effects
Ostarine and other SARMs have been associated with adverse effects involving hormonal, hepatic, and cardiovascular systems.
Potential adverse effects reported or associated with SARM exposure include:
- Changes in reproductive hormone levels
- Suppression of natural testosterone production
- Alterations in cholesterol concentrations
- Headache
- Nausea or gastrointestinal discomfort
- Fatigue
- Changes in libido
- Mood-related symptoms
The frequency and severity of these reactions are not fully characterized for all ostarine-containing products.
More serious safety concerns include:
- Liver injury
- Clinically significant hormonal suppression
- Adverse lipid changes
- Potential cardiovascular complications
- Reproductive health effects
- Unknown long-term consequences of exposure
Cases of liver injury have been reported in association with products marketed as SARMs, including ostarine-containing products.
However, product mislabeling, contamination, and the presence of additional substances can complicate the interpretation of some reports.
The FDA has also warned about serious safety concerns associated with SARMs, including possible heart attack and stroke risks.
Symptoms such as jaundice, dark urine, persistent abdominal pain, chest pain, or unexplained shortness of breath require prompt medical evaluation.
Warnings & Precautions
Ostarine is not an FDA-approved medication for human use.
Its investigational status means that important questions remain regarding long-term safety, appropriate clinical applications, and product quality.
Individuals with liver disease, cardiovascular conditions, abnormal cholesterol levels, or endocrine disorders may face additional concerns from exposure.
Ostarine can affect androgen-related signaling and may disrupt normal reproductive hormone regulation.
The absence of conversion into estrogen through aromatization does not mean that hormonal adverse effects cannot occur.
Safety during pregnancy and breastfeeding has not been established, and androgen receptor modulation may pose risks to fetal development.
Use in children and adolescents is particularly concerning because normal hormonal development may be affected.
Products sold as SARMs may also contain ingredients or concentrations that differ from their labels.
Storage & Handling
The supplied product descriptions identify Alpharine 10 as a package containing 90 oral tablets.
However, verified manufacturer storage instructions, stability data, and expiration specifications were not provided.
Exact storage conditions should be confirmed using authentic manufacturer documentation.
Keep chemical and pharmaceutical products in their original, clearly identified packaging and away from children and pets.
Do not assume that an unverified product is suitable for human use based on its packaging, tablet appearance, or online description.
Frequently Asked Questions (FAQs)
What is the active ingredient in Alpharine 10?
The product is described as containing ostarine, also known as MK-2866 or enobosarm.
How strong is each tablet?
Both supplied sources identify a labeled strength of 10 mg per tablet.
How many tablets are included?
Alpharine 10 is described as being supplied in a package containing 90 tablets.
Is ostarine an anabolic steroid?
No. Ostarine is a nonsteroidal selective androgen receptor modulator, although it can produce androgen-related biological effects.
Is Alpharine 10 FDA-approved?
No FDA approval for Alpharine 10 has been established. Ostarine itself is not FDA-approved for human use in the United States.
Conclusion & Medical Disclaimer
Alpharine 10 is marketed as an oral ostarine product. Its investigational status, potential adverse effects, and unverified quality require careful consideration.




Reviews
There are no reviews yet.